QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...

Related Keywords

United Kingdom ,Belgium ,Germany ,Netherlands ,Cambridge ,Cambridgeshire ,Canada ,Ireland ,Kasper Roet ,Kevin Eggan ,Prnewswire Quralis Corporation ,European Union ,Eggan Lab ,Alis Corporation ,Clinical Trial Regulation ,Trial Authorisation ,Clinical Trial Authorisation ,Quralis ,